Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
Status:
Terminated
Trial end date:
2020-04-16
Target enrollment:
Participant gender:
Summary
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice
daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with
RMS.